



The University of Western Ontario
Biohazards Subcommittee Meeting

Minutes of June 15th, 2012
9:30 a.m. – 11:00 a.m., SSB 4220

Present: Dr. J. Millar (Chair), Dr. S. Barr, Dr. G. Dekaban, Dr. S. Siu, J. Stanley, S. Seaton (OH&S Intern)

Regrets: Dr. T. deLangley, Dr. S. Koval, Dr. I. Welch

1.0 Introductions

None needed.

2.0 Approval of Minutes – May 11th, 2012

Motioned: Dr. S. Siu Seconded: Dr. S. Barr

3.0 Office Approvals

There were five office approvals.

4.0 Biological Agents Registry Forms

4.1 Mele, T.

Approved: In Table 1.2 the question regarding human pathogen should be marked as “No”.

4.2 Pin, C.

Tabled: This researcher’s personal research should be separated from research done in the Transgenic Facility, LRTGT (i.e. the work his/her grant does not fund). If Tamoxifen is being used in the Transgenic Facility, it should be used in accordance with the latest animal care protocol (to be stated in the summary). Section 5.0 should reflect E1A. The appendix includes some oncogenes. If these oncogenes are not being used this

should be indicated. The Transgenic Facility (LRTGT) should complete a separate form.

4.3 Rehmann, L. (Modification)

Approved: This protocol needs to be reviewed by Dr. S. Koval and can be approved once she is satisfied with it.

4.4 Feng, Q. (Modification)

Approved: No issues.

4.5 Allan, A. (Modification/Revisit, May 2012)

Approved: The containment level, 2 plus, should be stated on the modification form.

4.6 Kang, C. Y. (Revisit, December 2011)

Approved: In the summary, it states that work is not being done with Adenovirus-5. However, it is listed in Table 1.2. In table 1.2, with respect to the Adenovirus, the question regarding animal pathogen should be marked as "Yes". For Question 4.3.1, if work is being done with Adenovirus-5, the answer should be "Yes".

4.7 Reid, G. (Revisit, April 2012)

Approved: Level 2 plus. The lab should send the PHAC permit to Western's Biosafety Officer once it is received.

4.8 Ray, M. (Revisit, May 2012)

Approved: Effluent bacteria should be listed in Table 1.2. Table 3.2 should then be filled out as effluent waste could potentially contain Human Source materials. Workers should also be vaccinated against Hepatitis B and Polio. This protocol needs to be reviewed by Dr. S. Koval and can be approved once she is satisfied with it.

4.9 Chakraborty, C. (Revisit, May 2012)

Approved: Should Table 1.2 say that 20L of E. coli is cultured at one time? In Table 4.2 "phenotype" should be changed to "genotype". If SV neo has the SV 40 antigen in it, then the appropriate question in Section 5.0 should say "Yes". Since Cdc42 has oncogenic properties, it should be listed under potential oncogenes.

4.10 Cregan, S.

Approved: Clarification is needed as to the use of the mutant genes. A summary about the containment protocol is needed. In Table 1.2 the question about human pathogen should say “No” for E. coli and the question about animal pathogen should say “Yes” for Adenovirus. Once modified, it can be reviewed by Dr. Dekaban and Dr. Barr and approved.

4.11 Lu, W.

Approved: No issues.

4.12 Feldman, R.

Tabled: In the summary, full names should be used instead of abbreviations. In Table 1.2, for Adenovirus-5, the questions involving human and animal pathogen should both say “Yes”. The maximum quantity to be cultured at one time for Adenovirus-5 needs to be clarified as 100 µL is unlikely the maximum. In Table 4.3 more detail is needed as to the growth changes that occur once the gene is transduced.

4.13 Kim, S. O. (Revisit, April 2012)

Tabled: For Question 4.4, in relation to the E1A oncogene, it should say “Yes”. Clarification is required as to what work is done with c-ras and c-ras. The RAW 264.7 cells contain Abelson genes in retrovirus.

4.14 MacDonald, J. (Revisit, May 2012)

Approved: Clarification is required as to the source or supplier of the microorganisms being used. Page 1 of appendix (May 30, 2012) is provided as updated information.

4.15 Lui, E.

Approved: The storage amount of Lipopolysaccharides (LPS) is too high. The toxin needs to be stored in more than one location.

4.16 Jackson, M.

Approved: Clarification is required as to the source or supplier of the microorganisms being used. Page 1 of appendix (May 30, 2012) is provided as updated information.

4.17 Gunaratnam, L. (Modification)

Approved: The containment level should be stated as Level 2+.

Last Minute Additions

4.18 Others?

None.

5. Level 3 Access: Tamie Fulford (J. Stanley)

Tamie Fulford has gone through Level 3 Access Security Checks. Tamie has prior work experience in the Non-Human Primate Unit. In the future, information regarding prior work experience should be provided.

6. Viral Vector Policy (Revisit) (S. Barr, G. Dekaban)

Modifications were made to the document and will be submitted to the Biosafety Committee for review.

7. Next meeting date: July 13th? (J. Stanley)

Drs. Millar, Barr, Dekaban and Siu will be available on the 13th.

10. Other Business (J. Millar)

Due to the University's rebranding, the Human Resources website will be given a new appearance before the next Committee meeting.

11. Adjournment (J. Millar)

The meeting was adjourned at 10:35 am.